A Retrospective, Observational, Multi-centered Study to Validate a D3-D5 Embryo Prediction Tool and Assess Its Performance in a Clinical Setting.
Overview
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Future Fertility Inc.
- Enrollment
- 80
- Primary Endpoint
- The association between using MAGENTA Blast as an informative adjunctive aid and the prediction of blastocyst formation by Day 5 in embryos graded as Good/Fair
Overview
Brief Summary
This is a retrospective, observational, single-arm, multi-center study to evaluate the predictive performance of MAGENTA BLAST, an artificial intelligence (AI)-enabled software application, when used as analytical, adjunctive information to support Day 3 cleavage stage embryo predictions of blastocyst formation by Day 5.
Detailed Description
This retrospective, observational, single-arm, multi-centered study is designed to evaluate the predictive performance of MAGENTA Blast, an AI-enabled software, as adjunctive information to support Day 3 cleavage-stage embryo predictions of blastocyst formation by Day 5. The study will assess the association between embryo-level predictions generated using standard morphological evaluation with and without adjunctive MAGENTA Blast output, and observed blastocyst formation outcomes.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Women undergoing fresh IVF treatment using their own eggs
- •At least 18 years of age
- •Total antral follicle count (AFC) of at least 12 as measured by ultrasound prior to stimulation (in cases where AFC is performed)
- •Basal day 3 follicle-stimulating hormone levels (FSH) \< 10 IU (in cases where basal day 3 FSH is performed)
- •At least 8 normally fertilized eggs at the pronuclear (2PN) stage
- •Fertilization using only ejaculated sperm (fresh or frozen) - no surgically removed sperm
- •At least one two-cell embryo on Day 3
- •At least part of the embryo cohort is cultured until day 5 (i.e. 114-116 HPI)
Exclusion Criteria
- •Use of re-inseminated eggs (rescue ICSI)
- •Gestational carriers
- •Concurrent participation in another clinical study
- •Previous enrollment in this clinical study (i.e., one cycle data per patient)
- •History of cancer
- •Planned Day 3 laser-assisted hatching or embryos that underwent Day 3 biopsy for preimplantation genetic testing (PGT)
- •Low quality images
- •Lack of correlating reproductive outcomes (IVF lab results not available)
Arms & Interventions
Women undergoing fresh IVF treatment
Women undergoing fresh IVF treatment using their own eggs and are at least 18 years of age.
Intervention: MAGENTA Blast (Device)
Outcomes
Primary Outcomes
The association between using MAGENTA Blast as an informative adjunctive aid and the prediction of blastocyst formation by Day 5 in embryos graded as Good/Fair
Time Frame: 3 days
The association between blastocyst outcome predictions by Day 5 with adjunctive use of MAGENTA Blast and the observed blastocyst outcome (Yes/No) for embryos classified as Good/Fair quality will be quantified using Odds Ratio (OR) greater than 1 and corresponding 95% confidence intervals.
Secondary Outcomes
- The association between using MAGENTA Blast as an informative adjunctive aid and the prediction of blastocyst formation by Day 5 in all embryos(3 days)
- Blastocyst formation predicted by embryologists using traditional morphology only in all embryos as well as for the subset of embryos graded as Good/Fair(3 days)
- The association per embryologist between adjunctive use of MAGENTA Blast for Day 3 cleavage-stage embryo assessment and prediction of blastocyst formation by Day 5 in embryos graded as Good/Fair(3 days)